CI-949 is an inhibitor of allergic mediator release, used to suppress the release of histamine, leukotrienes C4/D4 (LTC4/LTD4), and thromboxane B2 (TXB2). It effectively inhibits the release of these mediators from human basophilic leukocytes stimulated by anti-IgE or N-formyl-methionyl-leucyl-phenylalanine (FMLP), as well as from antigen-challenged lung fragments of actively sensitized guinea pigs. In vivo, CI-949 protects actively sensitized guinea pigs against antigen-induced bronchoconstriction and collapse when administered intraperitoneally or orally prior to allergen challenge.